Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Psoriatic arthritis (PsA) is a chronic systemic inflammatory disorder characterized by the association of arthritis and periarticular inflammation in patients with psoriasis. In addition to a heterogeneous and variable clinical course, PsA is complex and multifaceted and may include prominent involvement in the peripheral and axial diarthrodial joints, the skin and nails, and in periarticular structures such as entheses. Simultaneous inflammation in the skin and musculoskeletal structures in a single patient, a relatively common scenario, often leads to marked decrease in function and quality of life. Thus, it is essential for the clinician to document the extent of disease involvement and craft a therapeutic plan that addresses the different domains of disease. In an effort to update previous treatment recommendations developed by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), several evidence-based, systemic reviews of therapies for PsA were completed, analyzed, and circulated for consensus.

Original publication

DOI

10.3899/jrheum.140875

Type

Journal article

Journal

J rheumatol

Publication Date

11/2014

Volume

41

Pages

2273 - 2276

Keywords

AXIAL DISEASE, DACTYLITIS, ENTHESITIS, NAIL PSORIASIS, PERIPHERAL ARTHRITIS, PSORIASIS, Antirheumatic Agents, Arthritis, Psoriatic, Evidence-Based Medicine, Female, Humans, Male, Practice Guidelines as Topic, Prognosis, Randomized Controlled Trials as Topic, Risk Assessment, Societies, Medical, Treatment Outcome